Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1394&sort=-program_officials
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=-program_officials", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=-program_officials", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1395&sort=-program_officials", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=-program_officials" }, "data": [ { "type": "Grant", "id": "9174", "attributes": { "award_id": "75N91019D00024-P00005-759102000004-2", "title": "COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) VARIANT TESTING", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-31", "end_date": "2022-08-30", "award_amount": 6477336, "principal_investigator": { "id": 24934, "first_name": "SALIBA", "last_name": "KATY", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1610, "ror": "", "name": "LEIDOS BIOMEDICAL RESEARCH, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "COVID SARS-CoV-2 Assessment Viral Evolution (SAVE) variant testing provides support for analysis of SARS-CoV-2 genome sequences from specimens collected in COVID-19 therapeutic and observational trials for genetic variants that could impact diagnostics, therapeutics, vaccine efficacy, and disease severity. COVID SAVE provides support for the analysis of the impact of SARS-CoV-2 variants on disease severity in animal models and in vitro neutralization assays. Additionally, COVID SAVE variant testing allows analysis of the evolution of SARS-CoV-2 and identification of future variants with potential public health impacts.", "keywords": [ "2019-nCoV", "Animal Disease Models", "Animal Model", "Biological Assay", "COVID-19", "COVID-19 therapeutics", "Clinical Research", "Complement", "Contracts", "Diagnostic", "Epidemiology", "Evolution", "Funding", "Future", "Genome", "Hypersensitivity", "Immune Evasion", "Immune response", "In Vitro", "Infection", "Institutes", "Monoclonal Antibodies", "Public Health", "Research Personnel", "SARS-CoV-2 genome", "SARS-CoV-2 variant", "Severity of illness", "Specimen", "Testing", "Therapeutic", "Variant", "Viral", "Virus", "coronavirus disease", "genetic variant", "genome sequencing", "human data", "targeted treatment", "vaccine efficacy", "whole genome" ], "approved": true } }, { "type": "Grant", "id": "9175", "attributes": { "award_id": "75N92020C00019-P00002-9999-1", "title": "RAPID ACCELERATION OF DIAGNOSTICS (RADX) TECH PROGRAM: PROJECT NO 5218 MATMACORP SARS-COV-2 HIGH THROUGHPUT LABORATORY CAPACITY SCALE-UP", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-29", "end_date": "2021-04-30", "award_amount": 4947000, "principal_investigator": { "id": 24935, "first_name": "PHIL", "last_name": "KOZERA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1804, "ror": "", "name": "MATERIALS/ MACHINES CORPORATION/AMERICA", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1804, "ror": "", "name": "MATERIALS/ MACHINES CORPORATION/AMERICA", "address": "", "city": "", "state": "NE", "zip": "", "country": "United States", "approved": true }, "abstract": "MatMaCorp is an animal health diagnostics company that collaborates with agencies including the Department of Homeland Security (DHS) Science and Technology group and USDA's Meat Animal Research Center (USMARC). In February of 2020, we shifted focus to human health in response to the COVID-19 pandemic. We are working to utilize our portable diagnostic platform, the Solas 8 fluorescent detection device and proprietary tests, with features supportive of rapid, mobile human diagnostics. Our device uses molecular probes to detect and identify specific DNA or RNA (target) sequences, in addition to a mutation or variation (SNP) within a sequence. Additional Features: · Touchscreen interface · USB Ports · Wi-Fi enabled · Mobile Application · Automated calling of results Additionally, our assays are lyophilized and do not require pipettes, centrifuges, or refrigeration and have a twelve-month shelf life. The Covid-19 kits are made for lab-use or field-use, providing flexibility and accessibility. Whether at a workplace, in a lab, or in a mobile testing center, results can be generated in real-time without specialized lab equipment, technical skills, or controlled conditions.", "keywords": [ "2019-nCoV", "Animal Experimentation", "Animals", "Biological Assay", "COVID-19", "COVID-19 pandemic", "DNA", "Detection", "Devices", "Diagnostic", "Freeze Drying", "Health", "Human", "Laboratories", "Life", "Meat", "Molecular Probes", "Mutation", "RADx Tech", "RNA", "Refrigeration", "Science", "Security", "Technical Expertise", "Technology", "Testing", "Time", "Variant", "Workplace", "diagnostic platform", "flexibility", "laboratory equipment", "mobile application", "portability", "programs", "response", "scale up", "touchscreen", "wireless fidelity" ], "approved": true } }, { "type": "Grant", "id": "9176", "attributes": { "award_id": "75N92020C00020-P00001-9999-1", "title": "RADX TECH - MAXIM BIOMEDICAL INC. SARS-COV-2 ANTIGEN RAPID TEST", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-28", "end_date": "2021-08-27", "award_amount": 3153450, "principal_investigator": { "id": 24936, "first_name": "JONATHAN", "last_name": "MAA", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1805, "ror": "", "name": "MAXIM BIOMEDICAL, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1805, "ror": "", "name": "MAXIM BIOMEDICAL, INC.", "address": "", "city": "", "state": "MD", "zip": "", "country": "United States", "approved": true }, "abstract": "Maxim Biomedical, Inc. (Maxim), headquartered in Maryland, USA, was formed in May 2005 to develop and provide high quality, in-vitro diagnostic (IVD) and Point-of-Care (POC) testing solutions. Our FDA cGMP approved and ISO13485:2016 certified facility is equipped with state-of-the-art laboratories for in-vitro diagnostic production. In response to the COVID-19 pandemic and in collaboration with the US Department of Defense (DoD), Maxim has in-house developed the Maxim SARS-CoV-2 Antigen Rapid Test Kit as a single-use qualitative lateral flow immunoassay to detect the circulating antigens of SARS-CoV-2. This point-of-care (POC) test is currently suitable for use with nasopharyngeal specimens from individuals suspected of COVID-19 infection and requires 10 minutes for a complete readout. A small-batch production (5000 units) of Maxim’s SARS-CoV-2 Antigen Rapid Test prototype has undergone and completed performance evaluation testing by the DoD’s Defense Biological Product Assurance Office (DBPAO) with highly promising results (see Prior Work). Optimizations are already ongoing to improve the sensitivity and specificity and to ensure that the product can be manufactured in a scalable manner. Maxim is currently seeking funding to rapidly scale up production capacity to be able to meet DoD’s demand of an estimated minimum of 1 MM tests/month by 07/15/20. Based on our current stage of development, we believe that Maxim’s Rapid Antigen Test can meet the milestones of this RADx program to rapidly deploy test kits to the general public.", "keywords": [ "Aphorisms", "Biological Products", "COVID-19 pandemic", "Collaborations", "Cyclic GMP", "Department of Defense", "Development", "Diagnostic Reagent Kits", "Ensure", "Funding", "General Population", "Immunoassay", "Individual", "Laboratories", "Lateral", "Maryland", "Performance", "Production", "RADx", "RADx Tech", "SARS-CoV-2 antigen", "SARS-CoV-2 infection", "Sensitivity and Specificity", "Specimen", "Testing", "Work", "antigen test", "base", "evaluation/testing", "improved", "in-vitro diagnostics", "point of care testing", "programs", "prototype", "rapid test", "response", "scale up" ], "approved": true } }, { "type": "Grant", "id": "9182", "attributes": { "award_id": "272201800013I-P00002-759302000004-1", "title": "Task V7: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine Candidates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-27", "end_date": "2022-08-26", "award_amount": 106598, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Biological", "Bioterrorism", "COVID-19", "COVID-19 testing", "COVID-19 vaccine", "Clinical", "Communicable Diseases", "Contracts", "Development", "Emerging Communicable Diseases", "Feasibility Studies", "Investigational New Drug Application", "Licensing", "Sampling", "Services", "Vaccines", "evaluation/testing", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9183", "attributes": { "award_id": "272201800013I-0-759302000004-3", "title": "Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-27", "end_date": "2022-08-26", "award_amount": 98800, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Biological Products", "Bioterrorism", "COVID-19", "Clinical", "Communicable Diseases", "Contracts", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "efficacy testing", "evaluation/testing", "immunogenicity", "novel coronavirus", "novel vaccines", "product development", "testing services", "therapeutic development", "vaccine candidate" ], "approved": true } }, { "type": "Grant", "id": "9184", "attributes": { "award_id": "272201800013I-0-759302000004-2", "title": "Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-27", "end_date": "2022-08-26", "award_amount": 113397, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Biological Products", "Bioterrorism", "COVID-19", "Clinical", "Communicable Diseases", "Contracts", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "efficacy testing", "evaluation/testing", "immunogenicity", "novel coronavirus", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9185", "attributes": { "award_id": "272201800013I-0-759302000004-1", "title": "Task V11: Clinical and NHP Sample Testing for SARS-CoV-2 Vaccine and Other Biological Product Candidates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-27", "end_date": "2022-08-26", "award_amount": 892055, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. Task areas include: 1) administrative management and technical support including training and workshops, and quality oversight and management (site visits, critical stage audits, and final study report audits), 2) development, qualification and validation of immune assays, 3) immunogenicity and efficacy testing, 4) non-clinical and clinical sample testing, and 5) safety/toxicology studies. These services will facilitate the development and introduction of new vaccine candidates and biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Area", "Biological", "Biological Products", "Bioterrorism", "COVID-19", "Clinical", "Communicable Diseases", "Contracts", "Development", "Educational workshop", "Emerging Communicable Diseases", "Feasibility Studies", "Immunology procedure", "Investigational New Drug Application", "Licensing", "Office of Administrative Management", "Reporting", "Safety", "Sampling", "Services", "Site Visit", "Testing", "Toxicology", "Training", "Vaccines", "Validation", "efficacy testing", "evaluation/testing", "immunogenicity", "novel coronavirus", "novel vaccines", "product development", "testing services", "vaccine candidate", "vaccine development" ], "approved": true } }, { "type": "Grant", "id": "9186", "attributes": { "award_id": "272201800013I-P00002-759302000004-3", "title": "Task V7: Clinical and NHP Sample Testing for SARS-CoV-2 Biological Product Candidates", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-27", "end_date": "2022-08-26", "award_amount": 172276, "principal_investigator": { "id": 24843, "first_name": "THOMAS", "last_name": "RUDGE", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 1789, "ror": "", "name": "BATTELLE CENTERS/PUB HLTH RES & EVALUATN", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "The Evaluation and Testing Services (ETS) for Vaccines and Other Biologics for Infectious Diseases contract provides a variety of product development services from early feasibility studies through activities required for the submission of Biologic License Application (BLA) and/or Investigational New Drug (IND) applications. These services will facilitate the development and introduction of new biologics (regulated by CBER) against potential agents of bioterrorism and emerging and re-emerging infectious diseases.", "keywords": [ "2019-nCoV", "Biological", "Biological Products", "Bioterrorism", "COVID-19", "COVID-19 testing", "COVID-19 therapeutics", "Clinical", "Communicable Diseases", "Contracts", "Development", "Emerging Communicable Diseases", "Feasibility Studies", "Investigational New Drug Application", "Licensing", "Sampling", "Services", "Vaccines", "evaluation/testing", "product development", "testing services", "therapeutic development" ], "approved": true } }, { "type": "Grant", "id": "9188", "attributes": { "award_id": "5U01CK000592-02", "title": "Analysis and Simulation of Bacterial Infections and Resource Strain in Hospitals during the COVID-19 Pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-01", "end_date": "2025-07-31", "award_amount": 1200000, "principal_investigator": { "id": 24943, "first_name": "Sen", "last_name": "Pei", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 20718, "first_name": "JEFFREY L", "last_name": "SHAMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": "Antimicrobial resistant (AR) pathogens remain a major cause of healthcare associated infections (HAIs) in the United States. Indeed, the prevalence of these existing and emerging drug-resistant agents continues to impose a heavy burden on U.S. healthcare systems. To better control existing AR pathogen-associated HAIs and prepare for the possible emergence of a novel AR organism, better, more targeted identification and intervention strategies need to be developed. Here, for this Modeling Infectious Diseases in Healthcare Research Projects to Improve Prevention Research and Healthcare Delivery (MInD Healthcare) network project, we propose to develop a hierarchy of new model-inference systems capable of simulating and forecasting HAI outbreaks, quantifying individual patient colonization risk, and identifying optimal intervention approaches. Specifically, we will use hospitalization records and diagnostic data for multiple AR pathogens from four major hospitals in New York City to conduct a series of modeling studies. We will develop two mathematical modeling structures: 1) a metapopulation model capable of simulating AR pathogen transmission dynamics across multiple healthcare facilities; and 2) an agent-based model capable of simulating individual- level patient infection status, transmission dynamics, and movements within multiple hospitals. These models will be used in conjunction with Bayesian inference methods to simulate observed outbreaks of AR pathogens, estimate critical epidemiological characteristics and asymptomatic carriage probabilities among individual patients, and support development of an AR pathogen forecasting system. As the models are high dimension and the observations are sparse, new inference methods, capable of data augmentation and efficient model optimization, will also be developed. Additionally, we will use the optimized model structures to run free simulations testing the effectiveness of six interventions: 1) hand hygiene and barrier precautions; 2) isolation of infections; 3) environmental cleaning; 4) active patient screening within hospitals; 5) contact tracing; and 6) screening at admission. These interventions will be tested singly and in bundles and used to inform targeted control approaches. Further, we will develop a framework for identifying intervention bundles that maximally reduce HAI rates given cost and logistical constraints. Lastly, we propose to collaborate with the CDC and the other research groups in the MInD Healthcare network to develop standardized intervention scenarios and inter-comparisons of simulated intervention outcomes among the different model forms used across the network.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "9189", "attributes": { "award_id": "6U01CK000592-01M001", "title": "Analysis and Simulation of Bacterial Infections and Resource Strain in Hospitals during the COVID-19 Pandemic", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [], "program_reference_codes": [], "program_officials": [], "start_date": "2020-08-01", "end_date": "2025-07-31", "award_amount": 650000, "principal_investigator": { "id": 24943, "first_name": "Sen", "last_name": "Pei", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [ { "id": 20718, "first_name": "JEFFREY L", "last_name": "SHAMAN", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true } ] } ], "awardee_organization": { "id": 781, "ror": "", "name": "COLUMBIA UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NY", "zip": "", "country": "United States", "approved": true }, "abstract": null, "keywords": [], "approved": true } } ], "meta": { "pagination": { "page": 1394, "pages": 1424, "count": 14236 } } }